DE69328503D1 - Mycobacterium vaccae zur Behandlung von lang andauernden Autoimmunerkrankungen - Google Patents

Mycobacterium vaccae zur Behandlung von lang andauernden Autoimmunerkrankungen

Info

Publication number
DE69328503D1
DE69328503D1 DE69328503T DE69328503T DE69328503D1 DE 69328503 D1 DE69328503 D1 DE 69328503D1 DE 69328503 T DE69328503 T DE 69328503T DE 69328503 T DE69328503 T DE 69328503T DE 69328503 D1 DE69328503 D1 DE 69328503D1
Authority
DE
Germany
Prior art keywords
treatment
long
autoimmune diseases
mycobacterium vaccae
lasting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69328503T
Other languages
English (en)
Other versions
DE69328503T2 (de
Inventor
John Lawson Stanford
Graham Arthur William Rook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Silence Therapeutics PLC
Original Assignee
Stanford Rook Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanford Rook Ltd filed Critical Stanford Rook Ltd
Application granted granted Critical
Publication of DE69328503D1 publication Critical patent/DE69328503D1/de
Publication of DE69328503T2 publication Critical patent/DE69328503T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Soil Working Implements (AREA)
  • Storage Of Fruits Or Vegetables (AREA)
  • External Artificial Organs (AREA)
  • Saccharide Compounds (AREA)
DE69328503T 1992-02-21 1993-02-19 Mycobacterium vaccae zur Behandlung von lang andauernden Autoimmunerkrankungen Expired - Fee Related DE69328503T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929203814A GB9203814D0 (en) 1992-02-21 1992-02-21 Treatment of long term auto-immune conditions

Publications (2)

Publication Number Publication Date
DE69328503D1 true DE69328503D1 (de) 2000-05-31
DE69328503T2 DE69328503T2 (de) 2000-08-24

Family

ID=10710862

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69328503T Expired - Fee Related DE69328503T2 (de) 1992-02-21 1993-02-19 Mycobacterium vaccae zur Behandlung von lang andauernden Autoimmunerkrankungen
DE69309915T Expired - Fee Related DE69309915T2 (de) 1992-02-21 1993-02-19 Mycobacterium Vaccae zur Behandlung von langwierigen Autoimmunerkrankungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69309915T Expired - Fee Related DE69309915T2 (de) 1992-02-21 1993-02-19 Mycobacterium Vaccae zur Behandlung von langwierigen Autoimmunerkrankungen

Country Status (24)

Country Link
US (1) US5885588A (de)
EP (2) EP0763361B1 (de)
JP (1) JPH07506093A (de)
KR (1) KR100275862B1 (de)
AT (2) ATE151641T1 (de)
AU (2) AU675421B2 (de)
BG (1) BG99054A (de)
BR (1) BR9305946A (de)
CA (1) CA2130117A1 (de)
CZ (1) CZ282651B6 (de)
DE (2) DE69328503T2 (de)
DK (2) DK0630259T3 (de)
ES (2) ES2145968T3 (de)
FI (1) FI943849A0 (de)
GB (1) GB9203814D0 (de)
GR (2) GR3024113T3 (de)
HU (1) HU218347B (de)
NO (1) NO311169B1 (de)
NZ (1) NZ249518A (de)
RO (1) RO117833B1 (de)
RU (1) RU2124367C1 (de)
SK (1) SK99994A3 (de)
UA (1) UA35583C2 (de)
WO (1) WO1993016727A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9406301D0 (en) * 1994-03-30 1994-05-25 Univ London Immunotherapeutic agent and its use
IL110011A (en) * 1994-06-13 2004-09-27 Yeda Res & Dev Pharmacological preparations for the treatment of schizophrenia
GB9505658D0 (en) * 1995-03-21 1995-05-10 Univ London Hormone and growth factor mimetics
US6056964A (en) * 1995-03-29 2000-05-02 Stanford Rook Limited Immunotherapeutic agent and its use
US6406704B1 (en) 1996-08-29 2002-06-18 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
AU741016B2 (en) * 1996-08-29 2001-11-22 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6160093A (en) * 1996-08-29 2000-12-12 Genesis Researth And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US5985287A (en) * 1996-08-29 1999-11-16 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
BR9713959A (pt) * 1996-12-18 2000-04-11 Stanford Rook Ltd Uso de material antigênico e/ou imunorregulatório derivado da mycobacterium vaccae, composição compreedendo o mesmo, e, processo para regulação descendente da atividade th2 do sistema imunológico de um indivìduo
US6878377B2 (en) 1996-12-18 2005-04-12 Stanford Rook Limited Mycobacterium vaccae for down-regulation of the Th2 activity of the immune system
IL136821A0 (en) * 1997-12-23 2001-06-14 Genesis Res & Dev Corp Ltd Compositions derived from mycobacterium vaccae and methods for their use
US6328978B1 (en) 1997-12-23 2001-12-11 Genesis Research & Development Corp. Ltd. Methods for the treatment of immunologically-mediated skin disorders
US5968524A (en) * 1997-12-23 1999-10-19 Genesis Research & Development Corp. Methods and compounds for the treatment of immunologically-mediated psoriasis
US6350457B1 (en) 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
JP2003510335A (ja) * 1999-08-06 2003-03-18 コリクサ コーポレイション 自己免疫疾患の処置のためのワクチン
GB0010496D0 (en) * 2000-04-28 2000-06-14 Stanford Rook Ltd Treatment of conditions of the central nervous system
GB0106985D0 (en) * 2001-03-20 2001-05-09 Stanford Rook Ltd Immunotherapeutic agent
GB0106986D0 (en) * 2001-03-20 2001-05-09 Stanford Rook Ltd Immunotherapeutic agent
DE602004028038D1 (de) * 2003-11-14 2010-08-19 Ucl Business Plc Immunmodulator mit ganzzell-tsukamurella bakterien

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
IL71683A0 (en) * 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
DK0556248T3 (da) * 1990-11-08 1997-10-27 Univ London Mycobacterium som adjuvans til antigener

Also Published As

Publication number Publication date
EP0630259A1 (de) 1994-12-28
WO1993016727A1 (en) 1993-09-02
GR3033772T3 (en) 2000-10-31
CA2130117A1 (en) 1993-09-02
DK0630259T3 (da) 1997-09-15
AU3637793A (en) 1993-09-13
DK0763361T3 (da) 2000-08-07
CZ282651B6 (cs) 1997-08-13
DE69328503T2 (de) 2000-08-24
AU675421B2 (en) 1997-02-06
EP0763361A3 (de) 1997-03-26
HU218347B (hu) 2000-08-28
HUT69941A (en) 1995-09-28
ES2145968T3 (es) 2000-07-16
SK99994A3 (en) 1995-05-10
EP0763361B1 (de) 2000-04-26
BR9305946A (pt) 1997-10-21
ATE192046T1 (de) 2000-05-15
DE69309915D1 (de) 1997-05-22
AU7188796A (en) 1997-02-06
RU2124367C1 (ru) 1999-01-10
NO943082D0 (no) 1994-08-22
CZ202394A3 (en) 1995-02-15
US5885588A (en) 1999-03-23
EP0763361A2 (de) 1997-03-19
FI943849A0 (fi) 1994-08-22
KR950700755A (ko) 1995-02-20
GR3024113T3 (en) 1997-10-31
ATE151641T1 (de) 1997-05-15
ES2104131T3 (es) 1997-10-01
NZ249518A (en) 1997-07-27
UA35583C2 (uk) 2001-04-16
JPH07506093A (ja) 1995-07-06
GB9203814D0 (en) 1992-04-08
HU9402422D0 (en) 1994-10-28
KR100275862B1 (ko) 2000-12-15
BG99054A (en) 1995-08-28
AU706122B2 (en) 1999-06-10
NO311169B1 (no) 2001-10-22
RU94045825A (ru) 1997-02-20
RO117833B1 (ro) 2002-08-30
EP0630259B1 (de) 1997-04-16
DE69309915T2 (de) 1997-07-24
NO943082L (no) 1994-10-17

Similar Documents

Publication Publication Date Title
ATE192046T1 (de) Mycobacterium vaccae zur behandlung von lang andauernden autoimmunerkrankungen
ATE132755T1 (de) Mycobacterium vaccae in der behandlung von uveitis
ATE234921T1 (de) Osteoinduktive zusammensetzungen
DE69202019D1 (de) Verwendung von essentiellen Fettsäuren zur Herstellung eines Arzneimittels zur Behandlung von AIDS.
DE69026506D1 (de) Biologisches präparat und seine verwendung
RU93004600A (ru) Применение mycobacterium vaccae, способ лечения, продукт m vaccae, иммунотерапевтический агент
ATE148628T1 (de) 5-methylisoxazol-4-carbonsäure-anilide und 2- hydroxyethyliden-cyanoessigsäure-anilide zur behandlung von augenkrankheiten
DE69305267D1 (de) Zusammensetzung zur Behandlung von Mastitis und Metritis
DE69116606D1 (de) Bacterin zur Behandlung von Necrophorum-Krankheiten und Verfahren zur Herstellung
FI901371A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten halogeeni-3,4-dihydro-bentsotiopyranyyliamiinien valmistamiseksi
ATE315583T1 (de) Analoge des thymosin alpha 1
DE69128095D1 (de) Azelluläre impfstoffe
DE68914886D1 (de) Mittel zur Behandlung von Raynaud's Krankheit.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee